Paper Details

  1. Home
  2. Paper Details

Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.

Author: Ben-JonathanNira, KumarBhavna, KumarPawan, TakiarVinita, TuttleTraci R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explored the synergistic effect of soluble guanylate cyclase (sGC) stimulators with cisplatin in treating head and neck squamous cell carcinoma (HNSCC). The results showed that sGC stimulators effectively reduced HNSCC cell viability and enhanced apoptosis induced by cisplatin, even in cells with acquired resistance. These findings suggest that sGC stimulators may serve as valuable additions or alternatives to cisplatin in the treatment of HNSCC.
Paper Details　
Original Abstract of the Article :
Head and neck squamous cell carcinoma (HNSCC) is an aggressive and often fatal disease. Cisplatin is the most common chemotherapeutic drug in the treatment of HNSCC, but intrinsic and acquired resistance are frequent, and severe side effects occur at high doses. The second messenger cyclic GMP (cGMP...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28025101

データ提供：米国国立医学図書館（NLM）

Soluble Guanylate Cyclase Stimulators: Enhancing Cisplatin's Impact in Head and Neck Cancer

This research explores the potential of soluble guanylate cyclase (sGC) stimulators in enhancing the effectiveness of cisplatin, a common chemotherapy drug used to treat head and neck squamous cell carcinoma (HNSCC). HNSCC is an aggressive cancer with a high risk of recurrence, and finding ways to improve treatment outcomes is crucial. The study investigated the synergistic effects of sGC stimulators and cisplatin in reducing HNSCC cell viability and promoting apoptosis.

A New Approach to Cancer Treatment

The study revealed that sGC stimulators, when combined with cisplatin, significantly reduced HNSCC cell viability and enhanced apoptosis. Importantly, the sGC stimulators also demonstrated efficacy in overcoming cisplatin resistance, a major challenge in HNSCC treatment.

A Potential Boost for Cancer Therapy

The findings suggest that sGC stimulators could represent a valuable addition or alternative to cisplatin in the treatment of HNSCC. These drugs have the potential to improve treatment outcomes and potentially reduce the need for higher doses of cisplatin, minimizing the risk of severe side effects.

Dr. Camel's Conclusion

Imagine a camel traveling through a desert, seeking a way to overcome a challenging obstacle. SGC stimulators, when combined with cisplatin, act like a powerful ally, helping to combat HNSCC more effectively. This research offers hope for new strategies to improve the treatment of this aggressive cancer.
Date :
  1. Date Completed 2017-08-08
  2. Date Revised 2019-02-21
Further Info :

Pubmed ID

28025101

DOI: Digital Object Identifier

NIHMS841793

Related Literature

Article Analysis
・Side Effects of riociguat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.